Juvenescence Limited – Artificial Intelligence to Discover Drugs in a Multi-Year Multimillion Dollar …
TORTOLA, British Virgin Islands–(BUSINESS WIRE)–Juvenescence Limited (“Juvenescence”) is pleased to announce the launch of a joint venture with Insilico Medicine, Inc. (“Insilico Medicine”), a Baltimore-based company using artificial intelligence (“AI”) principally focusing on ageing and age-related diseases. The new joint venture, Juvenescence AI Limited (“Juvenescence AI”), will focus on developing a pipeline of new compounds licensed from Insilico Medicine and on building AI-driven tools for clinical development. This partnership will produce commercially attractive drugs for Juvenescence AI while validating Insilico Medicine’s innovative AI approach for drug discovery. Juvenescence made an undisclosed investment into Insilico Medicine simultaneously with the creation of the joint venture. “We are very pleased to partner with Alex Zhavoronkov and his team at Insilico Medicine. Artificial intelligence is set to increase efficiencies in many sectors, something sorely needed in drug development as evidenced by the prolonged decline in the sector’s productivity. Insilico Medicine’s approach has massive potential to reduce the cost associated with the discovery of new drugs,” said Juvenescence’s Chairman, Jim Mellon, adding, “We are excited by the potential for AI to streamline the longest and most costly portions of the drug development cycle: clinical trials. With Insilico Medicine’s help, we hope Juvenescence AI will both…
Link to Full Article: Juvenescence Limited – Artificial Intelligence to Discover Drugs in a Multi-Year Multimillion Dollar …
Sharing
